It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
DNA double-strand breaks (DSBs) are toxic to mammalian cells. However, during meiosis, more than 200 DSBs are generated deliberately, to ensure reciprocal recombination and orderly segregation of homologous chromosomes. If left unrepaired, meiotic DSBs can cause aneuploidy in gametes and compromise viability in offspring. Oocytes in which DSBs persist are therefore eliminated by the DNA-damage checkpoint. Here we show that the DNA-damage checkpoint eliminates oocytes via the pro-apoptotic BCL-2 pathway members Puma, Noxa and Bax. Deletion of these factors prevents oocyte elimination in recombination-repair mutants, even when the abundance of unresolved DSBs is high. Remarkably, surviving oocytes can extrude a polar body and be fertilised, despite chaotic chromosome segregation at the first meiotic division. Our findings raise the possibility that allelic variants of the BCL-2 pathway could influence the risk of embryonic aneuploidy.
If left unrepaired, meiotic DSBs are toxic to mammalian cells, thus oocytes in which DSBs persist are eliminated by the DNA-damage checkpoint. Here the authors provide insights into the roles of PUMA, NOXA and BAX during DNA damage checkpoint that eliminates Dmc1−/− and Msh5−/− oocytes.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details




1 The Francis Crick Institute, Sex Chromosome Biology Laboratory, London, UK (GRID:grid.451388.3) (ISNI:0000 0004 1795 1830)
2 Max Planck Institute for Biophysical Chemistry, Göttingen, Germany (GRID:grid.418140.8) (ISNI:0000 0001 2104 4211)
3 The Francis Crick Institute, Human Embryo and Stem Cell Laboratory, London, UK (GRID:grid.451388.3) (ISNI:0000 0004 1795 1830)
4 University of Oxford, Nuffield Department of Women’s and Reproductive Health, John Radcliffe Hospital, Oxford, UK (GRID:grid.4991.5) (ISNI:0000 0004 1936 8948); IVI-RMA, Oxford, UK (GRID:grid.4991.5)
5 Duke-NUS Graduate Medical School, Singapore, Singapore (GRID:grid.428397.3) (ISNI:0000 0004 0385 0924); KK Women’s and Children’s Hospital, Department of Reproductive Medicine, Singapore, Singapore (GRID:grid.414963.d) (ISNI:0000 0000 8958 3388)